Compare Stocks: CTOR, SION, FATE, and GALT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$0.79 +1.9%	$0.70	$0.49 ▼ $2.25	$72.31M	3.52	75,599 shs	13,949 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
GALT Galectin Therapeutics	$4.35 -2.9%	$3.90	$2.03 ▼ $7.13	$295.04M	0.38	333,667 shs	244,140 shs
SION Sionna Therapeutics	$6.75 -7.7%	$30.53	$4.01 ▼ $54.97	$330.50M	0.89	4.71 million shs	1.24 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+1.86%	+0.24%	+20.03%	+1.56%	-59.79%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
GALT Galectin Therapeutics	-2.90%	+5.07%	+45.48%	+86.70%	-3.12%
SION Sionna Therapeutics	-7.66%	+11.39%	-86.48%	-80.92%	-72.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$0.79 +1.9%	$0.70	$0.49 ▼ $2.25	$72.31M	3.52	75,599 shs	13,949 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
GALT Galectin Therapeutics	$4.35 -2.9%	$3.90	$2.03 ▼ $7.13	$295.04M	0.38	333,667 shs	244,140 shs
SION Sionna Therapeutics	$6.75 -7.7%	$30.53	$4.01 ▼ $54.97	$330.50M	0.89	4.71 million shs	1.24 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+1.86%	+0.24%	+20.03%	+1.56%	-59.79%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
GALT Galectin Therapeutics	-2.90%	+5.07%	+45.48%	+86.70%	-3.12%
SION Sionna Therapeutics	-7.66%	+11.39%	-86.48%	-80.92%	-72.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.33	Hold	$6.00	657.38% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	143.80% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	152.87% Upside
SION Sionna Therapeutics	2.00	Hold	$42.22	525.51% Upside

Current Analyst Ratings Breakdown

Latest CTOR, SION, FATE, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	SION Sionna Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.43 per share	N/A
FATE Fate Therapeutics	$6.65M	43.60	N/A	N/A	$1.28 per share	1.89
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($2.11) per share	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$5.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A

Latest CTOR, SION, FATE, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.25	0.73	0.34
FATE Fate Therapeutics	N/A	4.85	4.85
GALT Galectin Therapeutics	N/A	0.10	0.10
SION Sionna Therapeutics	N/A	20.05	20.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
FATE Fate Therapeutics	97.54%
GALT Galectin Therapeutics	11.68%
SION Sionna Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	9.82%
FATE Fate Therapeutics	4.74%
GALT Galectin Therapeutics	52.60%
SION Sionna Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.85 million	N/A
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
SION Sionna Therapeutics	35	45.21 million	42.91 million	N/A

CTOR, SION, FATE, and GALT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 3 at 10:15 AM | prnewswire.com

SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

September 2 at 2:54 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

September 1 at 5:12 PM | globenewswire.com

Sionna Therapeutics, Inc. (SION)

September 1 at 2:36 AM | finance.yahoo.com

SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

August 31, 2026 | globenewswire.com

BlackRock Inc. Purchases Shares of 1,474,769 Sionna Therapeutics, Inc. $SION

August 31, 2026 | marketbeat.com

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

August 27, 2026 | prnewswire.com

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

August 26, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna ...

August 25, 2026 | reflector.comR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

August 25, 2026 | globenewswire.com

Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations

August 25, 2026 | globenewswire.com

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 25, 2026 | globenewswire.com

Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 25, 2026 | globenewswire.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Average Rating of "Hold" by Analysts

August 24, 2026 | americanbankingnews.com

SION INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

August 20, 2026 | newsfilecorp.comN

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

August 19, 2026 | prnewswire.com

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

August 19, 2026 | prnewswire.com

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

August 19, 2026 | businesswire.com

Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of "Hold" by Analysts

August 19, 2026 | marketbeat.com

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...

August 18, 2026 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTOR, SION, FATE, and GALT Company Descriptions

Citius Oncology NASDAQ:CTOR

$0.79 +0.01 (+1.86%)

As of 09/3/2026 03:59 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Fate Therapeutics NASDAQ:FATE

$2.42 -0.03 (-1.22%)

As of 09/3/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Galectin Therapeutics NASDAQ:GALT

$4.35 -0.13 (-2.90%)

As of 09/3/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Sionna Therapeutics NASDAQ:SION

$6.75 -0.56 (-7.66%)

As of 09/3/2026 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, SION, FATE, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, SION, FATE, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, SION, FATE, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, SION, FATE, and GALT Company Descriptions

Citius Oncology NASDAQ:CTOR

Fate Therapeutics NASDAQ:FATE

Galectin Therapeutics NASDAQ:GALT

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, SION, FATE, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, SION, FATE, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, SION, FATE, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, SION, FATE, and GALT Company Descriptions

Citius Oncology NASDAQ:CTOR

Fate Therapeutics NASDAQ:FATE

Galectin Therapeutics NASDAQ:GALT

Sionna Therapeutics NASDAQ:SION

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools